CLASS III Drug recall · Reported 19 Jul 2017 · FDA Enforcement Report

Paroxetine Extended-Release Tablets USP, 5 mg recalled

Lupin Pharmaceuticals is recalling Paroxetine Extended-Release Tablets USP, 5 mg, distributed nationwide in the US. The recall was initiated on 22 Jun 2017 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLots: H605712, H605711, H605710, EXP November 2018; H702255, H702202 EXP March 2019
NDC68180-645, 68180-647, 68180-646
Quantity recalled12480 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0974-2017
FDA event ID
77606
Recalling firm
Lupin Pharmaceuticals, Baltimore, MD
Manufacturer
Lupin Pharmaceuticals, Inc.
Classification
Class III
Status
Terminated
Recall initiated
22 Jun 2017
FDA classified
12 Jul 2017
Reported
19 Jul 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay
Drug class
Antidepressants

Timeline

22 Jun 2017Recall initiated by company
12 Jul 2017Classified by FDA+20 days
19 Jul 2017Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, India, NDC: 68180-647-06

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Paroxetine Extended-Release Tablets USP, 5 mg recalled?

Yes. Lupin Pharmaceuticals recalled Paroxetine Extended-Release Tablets USP, 5 mg on 22 Jun 2017. The recall is Class III and its status is Terminated. Recall number D-0974-2017.

Why was it recalled?

Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study.

Which lots are affected?

Lots: H605712, H605711, H605710, EXP November 2018; H702255, H702202 EXP March 2019

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Lupin Pharmaceuticals

All 123
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIClobetasol Propionate Cream USP, 05% tube recalledClobetasol PropionateLupin PharmaceuticalsOtherNationwide
DrugCLASS IIprednisoLONE Acetate Ophthalmic Suspension recalledPrednisolone AcetateLupin PharmaceuticalsSterilityNationwide
DrugCLASS IIGlucagon Emergency Kit for Low Blood Sugar, Glucagon recalledGlucagonLupin PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILiraglutide Injection, 18 mg/ (6 mg/mL) recalledLiraglutideLupin PharmaceuticalsParticulate MatterNationwide
DrugCLASS IISertraline Hydrochloride Tablets USP, 100 mg recalledSertraline HydrochlorideLupin PharmaceuticalsPackaging DefectsNationwide

Other Paroxetine recalls

All 16